Mi K. Son

Incheon, Republic of Korea

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications

A combination of BR101801 and venetoclax enhances antitumor effect in DLBCL cells via c-Myc/Bcl-2/Mcl-1 triple targeting.

A combination of BR101801 and venetoclax enhances antitumor effect in DLBCL cells via c-Myc/Bcl-2/Mcl-1 triple targeting.

Journal: American journal of cancer research
Published: December 07, 2022

Combination Therapy of the Active KRAS-Targeting Antibody inRas37 and a PI3K Inhibitor in Pancreatic Cancer.

Combination Therapy of the Active KRAS-Targeting Antibody inRas37 and a PI3K Inhibitor in Pancreatic Cancer.

Journal: Biomolecules & therapeutics
Published: September 07, 2021

Synergistic radiosensitizing effect of BR101801, a specific DNA-dependent protein kinase inhibitor, in various human solid cancer cells and xenografts.

Synergistic radiosensitizing effect of BR101801, a specific DNA-dependent protein kinase inhibitor, in various human solid cancer cells and xenografts.

Journal: American journal of cancer research
Published: July 20, 2021

ANGPTL4 accelerates KRASG12D-Induced acinar to ductal metaplasia and pancreatic carcinogenesis.

ANGPTL4 accelerates KRASG12D-Induced acinar to ductal metaplasia and pancreatic carcinogenesis.

Journal: Cancer letters
Published: May 05, 2021

Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape.

Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape.

Journal: Cancer letters
Published: November 17, 2020

ANGPTL4 exacerbates pancreatitis by augmenting acinar cell injury through upregulation of C5a.

ANGPTL4 exacerbates pancreatitis by augmenting acinar cell injury through upregulation of C5a.

Journal: EMBO molecular medicine
Published: July 29, 2019

Metabolomics Approach Based on Multivariate Techniques for Blood Transfusion Reactions.

Metabolomics Approach Based on Multivariate Techniques for Blood Transfusion Reactions.

Journal: Scientific reports
Published: July 10, 2018

KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer.

KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer.

Journal: Cancer letters
Published: June 29, 2018

Corrigendum to "Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer" [Cancer Lett. 396 (2017) 155-166].

Corrigendum to "Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer" [Cancer Lett. 396 (2017) 155-166].

Journal: Cancer letters
Published: June 25, 2017

Radiosensitization of the PI3K inhibitor HS-173 through reduction of DNA damage repair in pancreatic cancer.

Radiosensitization of the PI3K inhibitor HS-173 through reduction of DNA damage repair in pancreatic cancer.

Journal: Oncotarget
Published: June 08, 2017

Tumor vessel normalization by the PI3K inhibitor HS-173 enhances drug delivery.

Tumor vessel normalization by the PI3K inhibitor HS-173 enhances drug delivery.

Journal: Cancer letters
Published: April 06, 2017

Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer.

Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer.

Journal: Cancer letters
Published: February 03, 2017
Showing 1-12 of 35

Last Updated: 09/26/2026